TEV-56278 is under clinical development by Teva Pharmaceutical Industries and currently in Phase I for Solid Tumor.
Innovation, institutions, integration, and infrastructure are the four key factors that will drive this sector ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback